Uric acid reduction: A new paradigm in the management of cardiovascular risk?

Dawson, J. , Quinn, T.J. and Walters, M. (2007) Uric acid reduction: A new paradigm in the management of cardiovascular risk? Current Medicinal Chemistry, 14(17), pp. 1879-1886.

Full text not currently available from Enlighten.

Abstract

Uric acid is the end-product of purine catabolism. Hyperuricaemia is implicated in disorders such as gout and urolithiasis and recent epidemiological evidence suggests an association between increasing uric acid levels and increased cardiovascular morbidity and mortality. A direct causal role remains to be established but recent studies of losartan, atorvastatin and fenofibrate suggest that uric acid reduction contributes to attenuation of cardiovascular risk. Furthermore, several small studies of xanthine oxidase inhibition (the most common method of uric acid reduction) have shown improvements in measures of cardiovascular and endothelial function of a similar magnitude to those of other proven preventative strategies. This review introduces the epidemiological data, discusses strategies to lower uric acid and outlines the available clinical trial data supporting uric acid reduction as a potential and novel method of reducing the burden of cardiovascular disease.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Dawson, Professor Jesse and Walters, Professor Matthew and Quinn, Professor Terry
Authors: Dawson, J., Quinn, T.J., and Walters, M.
College/School:College of Medical Veterinary and Life Sciences > School of Cardiovascular & Metabolic Health
College of Medical Veterinary and Life Sciences
College of Medical Veterinary and Life Sciences > School of Medicine, Dentistry & Nursing
Journal Name:Current Medicinal Chemistry
Publisher:Bentham Science Publishers Ltd.
ISSN:0929-8673
Related URLs:

University Staff: Request a correction | Enlighten Editors: Update this record